65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update / Luis Vicente Syro Moreno  

Público ISBD Título : 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Chemotherapy  neoplasms  neuroendocrine tumors  pituitary  temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update [documento electrónico] / Luis Vicente Syro Moreno,  . - 2018. Obra : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Chemotherapy  neoplasms  neuroendocrine tumors  pituitary  temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4186

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000800	AC-2018-087	Archivo digital	Producción Científica	Artículos científicos	Disponible

DICER1 gene mutations in endocrine tumors / Luis Vicente Syro Moreno  

Público ISBD Título : DICER1 gene mutations in endocrine tumors Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : DICER1  endocrine tumors  mutation  neoplasms  pathology Resumen : In this review, the importance of the DICER1 gene in the function of endocrine cells is discussed. There is conclusive evidence that DICER1 mutations play a crucial role in the development, progression, cell proliferation, therapeutic responsiveness and behavior of several endocrine tumors. We review the literature of DICER1 gene mutations in thyroid, parathyroid, pituitary, pineal gland, endocrine pancreas, paragangliomas, medullary, adrenocortical, ovarian and testicular tumors. Although significant progress has been made during the last few years, much more work is needed to fully understand the significance of DICER1 mutations. Mención de responsabilidad : Michael Solarski, Fabio Rotondo, William D Foulkes, John R Priest, Luis V Syro, Henriett Butz, Michael D Cusimano, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Mar;25(3):R197-R208. DOI (Digital Object Identifier) : 10.1530/ERC-17-0509 PMID : 29330195 En línea : https://erc.bioscientifica.com/view/journals/erc/25/3/ERC-17-0509.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4195 DICER1 gene mutations in endocrine tumors [documento electrónico] / Luis Vicente Syro Moreno,  . - 2018. Obra : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : DICER1  endocrine tumors  mutation  neoplasms  pathology Resumen : In this review, the importance of the DICER1 gene in the function of endocrine cells is discussed. There is conclusive evidence that DICER1 mutations play a crucial role in the development, progression, cell proliferation, therapeutic responsiveness and behavior of several endocrine tumors. We review the literature of DICER1 gene mutations in thyroid, parathyroid, pituitary, pineal gland, endocrine pancreas, paragangliomas, medullary, adrenocortical, ovarian and testicular tumors. Although significant progress has been made during the last few years, much more work is needed to fully understand the significance of DICER1 mutations. Mención de responsabilidad : Michael Solarski, Fabio Rotondo, William D Foulkes, John R Priest, Luis V Syro, Henriett Butz, Michael D Cusimano, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Mar;25(3):R197-R208. DOI (Digital Object Identifier) : 10.1530/ERC-17-0509 PMID : 29330195 En línea : https://erc.bioscientifica.com/view/journals/erc/25/3/ERC-17-0509.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4195

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000809	AC-2018-096	Archivo digital	Producción Científica	Artículos científicos	Disponible

From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal / Luis Vicente Syro Moreno  

Público ISBD Título : From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2017 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Nomenclature  pituitary tumors Resumen : The classification of neoplasms of adenohypophysial cells is misleading because of the simplistic distinction between adenoma and carcinoma, based solely on metastatic spread and the poor reproducibility and predictive value of the definition of atypical adenomas based on the detection of mitoses or expression of Ki-67 or p53. In addition, the current classification of neoplasms of the anterior pituitary does not accurately reflect the clinical spectrum of behavior. Invasion and regrowth of proliferative lesions and persistence of hormone hypersecretion cause significant morbidity and mortality. We propose a new terminology, pituitary neuroendocrine tumor (PitNET), which is consistent with that used for other neuroendocrine neoplasms and which recognizes the highly variable impact of these tumors on patients. Mención de responsabilidad : S L Asa, O Casar-Borota, P Chanson, E Delgrange, P Earls, S Ezzat, A Grossman, H Ikeda, N Inoshita, N Karavitaki, M Korbonits, E R Laws Jr, M B Lopes, N Maartens, I E McCutcheon, O Mete, H Nishioka, G Raverot, F Roncaroli, W Saeger, L V Syro, A Vasiljevic, C Villa, A Wierinckx, J Trouillas, and the attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016 Referencia : Endocr Relat Cancer. 2017 Apr;24(4):C5-C8. DOI (Digital Object Identifier) : 10.1530/ERC-17-0004 PMID : 28264912 En línea : https://erc.bioscientifica.com/view/journals/erc/24/4/C5.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4026 From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal [documento electrónico] / Luis Vicente Syro Moreno,  . - 2017. Obra : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Nomenclature  pituitary tumors Resumen : The classification of neoplasms of adenohypophysial cells is misleading because of the simplistic distinction between adenoma and carcinoma, based solely on metastatic spread and the poor reproducibility and predictive value of the definition of atypical adenomas based on the detection of mitoses or expression of Ki-67 or p53. In addition, the current classification of neoplasms of the anterior pituitary does not accurately reflect the clinical spectrum of behavior. Invasion and regrowth of proliferative lesions and persistence of hormone hypersecretion cause significant morbidity and mortality. We propose a new terminology, pituitary neuroendocrine tumor (PitNET), which is consistent with that used for other neuroendocrine neoplasms and which recognizes the highly variable impact of these tumors on patients. Mención de responsabilidad : S L Asa, O Casar-Borota, P Chanson, E Delgrange, P Earls, S Ezzat, A Grossman, H Ikeda, N Inoshita, N Karavitaki, M Korbonits, E R Laws Jr, M B Lopes, N Maartens, I E McCutcheon, O Mete, H Nishioka, G Raverot, F Roncaroli, W Saeger, L V Syro, A Vasiljevic, C Villa, A Wierinckx, J Trouillas, and the attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016 Referencia : Endocr Relat Cancer. 2017 Apr;24(4):C5-C8. DOI (Digital Object Identifier) : 10.1530/ERC-17-0004 PMID : 28264912 En línea : https://erc.bioscientifica.com/view/journals/erc/24/4/C5.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4026

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000621	AC-2017-010	Archivo digital	Producción Científica	Artículos científicos	Disponible

Autophagy in endocrine tumors / Luis Vicente Syro Moreno  

Público ISBD Título : Autophagy in endocrine tumors Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2015 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Autophagy  autophagy modulation  endocrine disease  neoplasia  therapeutic potential Resumen : Autophagy is an important intracellular process involving the degradation of cytoplasmic components. It is involved in both physiological and pathological conditions, including cancer. The role of autophagy in cancer is described as a ‘double-edged sword,’ a term that reflects its known participation in tumor suppression, tumor survival and tumor cell proliferation. Available research regarding autophagy in endocrine cancer supports this concept. Autophagy shows promise as a novel therapeutic target in different types of endocrine cancer, inhibiting or increasing treatment efficacy in a context- and cell-type dependent manner. At present, however, there is very little research concerning autophagy in endocrine tumors. No research was reported connecting autophagy to some of the tumors of the endocrine glands such as the pancreas and ovary. This review aims to elucidate the roles of autophagy in different types of endocrine cancer and highlight the need for increased research in the field. Mención de responsabilidad : Andrea Weckman, Fabio Rotondo, Antonio Di Ieva, Luis V Syro, Henriett Butz, Michael D Cusimano and Kalman Kovacs Referencia : Endoc Rel Cancer. 2015;22(4):205-18. DOI (Digital Object Identifier) : 10.1530/ERC-15-0042 En línea : https://erc.bioscientifica.com/view/journals/erc/22/4/R205.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3901 Autophagy in endocrine tumors [documento electrónico] / Luis Vicente Syro Moreno,  . - 2015. Obra : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Autophagy  autophagy modulation  endocrine disease  neoplasia  therapeutic potential Resumen : Autophagy is an important intracellular process involving the degradation of cytoplasmic components. It is involved in both physiological and pathological conditions, including cancer. The role of autophagy in cancer is described as a ‘double-edged sword,’ a term that reflects its known participation in tumor suppression, tumor survival and tumor cell proliferation. Available research regarding autophagy in endocrine cancer supports this concept. Autophagy shows promise as a novel therapeutic target in different types of endocrine cancer, inhibiting or increasing treatment efficacy in a context- and cell-type dependent manner. At present, however, there is very little research concerning autophagy in endocrine tumors. No research was reported connecting autophagy to some of the tumors of the endocrine glands such as the pancreas and ovary. This review aims to elucidate the roles of autophagy in different types of endocrine cancer and highlight the need for increased research in the field. Mención de responsabilidad : Andrea Weckman, Fabio Rotondo, Antonio Di Ieva, Luis V Syro, Henriett Butz, Michael D Cusimano and Kalman Kovacs Referencia : Endoc Rel Cancer. 2015;22(4):205-18. DOI (Digital Object Identifier) : 10.1530/ERC-15-0042 En línea : https://erc.bioscientifica.com/view/journals/erc/22/4/R205.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3901

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000481	AC-2015-034	Archivo digital	Producción Científica	Artículos científicos	Disponible

The 8q24 rs6983267G variant is associated with increased thyroid cancer risk / Alejandro Vélez Hoyos ; Carlos Simón Duque Fisher ; Alejandro Rios  

Público ISBD Título : The 8q24 rs6983267G variant is associated with increased thyroid cancer risk Tipo de documento : documento electrónico Autores : Alejandro Vélez Hoyos, ; Carlos Simón Duque Fisher, ; Alejandro Rios, Fecha de publicación : 2015 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Thyroid cancer  rs6983267G  8q24  genetic susceptibility Resumen : The G allele of the rs6983267 single-nucleotide polymorphism, located on chromosome 8q24, has been associated with increased risk of several cancer types. The association between rs6983267G and thyroid cancer (TC) has been tested in different populations, mostly of European ancestry, and has led to inconclusive results. While significant associations have been reported in the British and Polish populations, no association has been detected in populations from Spain, Italy and the USA. To further investigate the role of rs6983267G in TC susceptibility, we evaluated rs6983267 genotypes in three populations of different continental ancestry (British Isles, Colombia and Japan), providing a total of 3067 cases and 8575 controls. We detected significant associations between rs6983267G and TC in the British Isles (odds ratio (OR)=1.19, 95% CI: 1.11–1.27, P=4.03×10−7), Japan (OR=1.20, 95% CI: 1.03–1.41, P=0.022) and a borderline significant association of similar effect direction and size in Colombia (OR=1.19, 95% CI: 0.99–1.44, P=0.069). A meta-analysis of our multi-ethnic study and previously published non-overlapping datasets, which included a total of 5484 cases and 12 594 controls, confirmed the association between rs6983267G and TC (P=1.23×10−7, OR=1.13, 95% CI: 1.08–1.18). Our results therefore support the notion that rs6983267G is a bona fide TC risk variant that increases the risk of disease by ∼13%. Mención de responsabilidad : Ruta Sahasrabudhe, Ana Estrada, Paul Lott, Lynn Martin, Guadalupe Polanco Echeverry, Alejandro Velez, Gila Neta, Meiko Takahasi, Vladimir Saenko, Norisato Mitsutake, JTCMS Consortium; Emma Jaeguer, Carlos Simon Duque, Alejandro Rios, Mabel Bohorquez, Rodrigo Prieto, Angel Criollo, Magdalena Echeverry, Ian Tomlinson, CORGI Consortium; TCUKIN Consortiums; Luis G Carvajal Carmona Referencia : Endocr Relat Cancer. 2015 Oct;22(5):841-9. DOI (Digital Object Identifier) : 10.1530/ERC-15-0081 PMID : 26290501 En línea : https://erc.bioscientifica.com/view/journals/erc/22/5/841.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3938 The 8q24 rs6983267G variant is associated with increased thyroid cancer risk [documento electrónico] / Alejandro Vélez Hoyos, ; Carlos Simón Duque Fisher, ; Alejandro Rios,  . - 2015. Obra : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Thyroid cancer  rs6983267G  8q24  genetic susceptibility Resumen : The G allele of the rs6983267 single-nucleotide polymorphism, located on chromosome 8q24, has been associated with increased risk of several cancer types. The association between rs6983267G and thyroid cancer (TC) has been tested in different populations, mostly of European ancestry, and has led to inconclusive results. While significant associations have been reported in the British and Polish populations, no association has been detected in populations from Spain, Italy and the USA. To further investigate the role of rs6983267G in TC susceptibility, we evaluated rs6983267 genotypes in three populations of different continental ancestry (British Isles, Colombia and Japan), providing a total of 3067 cases and 8575 controls. We detected significant associations between rs6983267G and TC in the British Isles (odds ratio (OR)=1.19, 95% CI: 1.11–1.27, P=4.03×10−7), Japan (OR=1.20, 95% CI: 1.03–1.41, P=0.022) and a borderline significant association of similar effect direction and size in Colombia (OR=1.19, 95% CI: 0.99–1.44, P=0.069). A meta-analysis of our multi-ethnic study and previously published non-overlapping datasets, which included a total of 5484 cases and 12 594 controls, confirmed the association between rs6983267G and TC (P=1.23×10−7, OR=1.13, 95% CI: 1.08–1.18). Our results therefore support the notion that rs6983267G is a bona fide TC risk variant that increases the risk of disease by ∼13%. Mención de responsabilidad : Ruta Sahasrabudhe, Ana Estrada, Paul Lott, Lynn Martin, Guadalupe Polanco Echeverry, Alejandro Velez, Gila Neta, Meiko Takahasi, Vladimir Saenko, Norisato Mitsutake, JTCMS Consortium; Emma Jaeguer, Carlos Simon Duque, Alejandro Rios, Mabel Bohorquez, Rodrigo Prieto, Angel Criollo, Magdalena Echeverry, Ian Tomlinson, CORGI Consortium; TCUKIN Consortiums; Luis G Carvajal Carmona Referencia : Endocr Relat Cancer. 2015 Oct;22(5):841-9. DOI (Digital Object Identifier) : 10.1530/ERC-15-0081 PMID : 26290501 En línea : https://erc.bioscientifica.com/view/journals/erc/22/5/841.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3938

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000523	AC-2015-076	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 5 / 5) Por página: 25 50 100 200